Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma.
The feasibility of allogeneic haematopoietic stem-cell transplantation (allo-HSCT) in 11 patients with adult T-cell leukaemia/lymphoma (ATL) (6 acute, 4 lymphoma, 1 chronic type) was evaluated. The preparative regimens (9 conventional, 2 reduced-intensity) were tolerable. Five patients developed acute graft-versus-host disease (GVHD), and three, extensive chronic GVHD. All 10 patients who survived > 30 d achieved complete remission. Estimated 1-year overall and disease-free survival rates were 53 +/- 30% and 45 +/- 29% respectively. Four patients remain alive and disease-free at a median follow-up of 25 months. The others died of transplantation-related complications. This pilot study suggests that allo-HSCT in ATL should be evaluated further.
Kami
Masahiro
M
Department of Haematology, Toranomon Hospital, Tokyo, Japan. mkami@ncc.go.jp
Hamaki
Tamae
T
Miyakoshi
Shigesaburo
S
Murashige
Naoko
N
Kanda
Yoshinobu
Y
Tanosaki
Ryuji
R
Takaue
Yoichi
Y
Taniguchi
Shuichi
S
Hirai
Hisamaru
H
Ozawa
Keiya
K
Kasai
Masaharu
M
D000208:Acute Disease; D002908:Chronic Disease; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease; D020544:Graft vs Leukemia Effect; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome